Printer Friendly

Virco HIV Resistance Tests Can Predict Response to Therapy for Up to Two Years.

BUENOS AIRES, Argentina, July 10 /PRNewswire/ --

A study presented today at the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment shows that Virco's resistance tests can predict clinical response to HIV treatment for up to two years. Patients who received three or more "active drugs" (as measured by the resistance tests) experienced significantly better clinical responses than patients receiving fewer active drugs. This is the first evidence of the long-term benefits of resistance testing, previous studies typically only lasting 16-24 weeks.

The retrospective study of 681 HIV-positive patients receiving care from the Chelsea and Westminster Hospital HIV Clinic, London, UK used the VirtualPhenotype(TM) and Antivirogram(TM) resistance tests to estimate the number of drugs to which each patient's virus was still susceptible (the number of active drugs). The viral load and CD4 cell counts were then compared for patients receiving 0, 1, 2, 3 or 4 active drugs. Both tests were found to be equally and highly significant predictors of outcome over 96 weeks. Patients receiving three or four active drugs experienced significantly greater reductions in viral load and increases in CD4 cell counts over the 96- week study, and a greater proportion achieved undetectable viral loads.

"The results of this study of HIV patients in our clinic indicate that resistance testing can be useful in helping physicians select the optimum combination of drugs for each patient, thereby maximizing their response to treatment over the long-term," said Professor Brian Gazzard, Consultant Physician and Director of HIV Research, Chelsea and Westminster Hospital HIV Clinic, London, UK, and lead investigator of the study.

The study also concluded that patients who changed therapy at the time the resistance testing was conducted experienced a "vastly superior response compared to those who did not". Almost 80% of patients who changed therapy at the time of resistance testing received three or four active drugs compared with just 23% of those who did not change.

"We are extremely encouraged by these results," said Neil Graham, MD, Vice President of Clinical and Medical Affairs at Tibotec-Virco. "These substantive data from clinical practice have been collected by one of the foremost HIV clinics in Europe and indicate that the benefit of resistance testing can be substantial and long-lasting."

Tibotec-Virco Background

Tibotec-Virco is a multinational biotechnology company with operating subsidiaries in the United States, Belgium, the United Kingdom, and Ireland. Tibotec-Virco sells its resistance testing services under the name of Virco via Quest Diagnostics, Laboratory Corporation of America Holdings (LabCorp) and ARUP Laboratories in the USA, SRL in Japan, as well as directly to HIV/AIDS centres in Europe, Canada and Australia.

The Tibotec-Virco group was formed from the merger of Virco Group NV and Tibotec Group NV on March 14, 2001 and brings together the complementary expertise of Tibotec in drug discovery and development and that of Virco in pharmacogenomics and molecular diagnostics. Tibotec-Virco applies the latest techniques in pharmacogenomics, molecular biology, drug discovery and development, and artificial intelligence to develop individualised disease management products, services and technologies in HIV, other infectious diseases and cancer with the ultimate aim of enhancing and extending peoples' lives.

Tibotec-Virco is widely regarded as a world leader in HIV resistance testing and has developed some of the most widely available and trusted diagnostics in the world. The company has a number of genomics-based diagnostic tests under development for use in the management of hepatitis and cancer. The current focus of the company's drug discovery and development activities is the clinical development of a number of HIV/AIDS drugs that are active against strains of HIV that have developed drug resistance (a major cause of treatment failure).

For further information, please visit Tibotec-Virco's website: .
COPYRIGHT 2001 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 10, 2001
Previous Article:Southwest Airlines Names New Marketing Manager for Houston Area.
Next Article:Lansing Named Senior Vice President of Scripps Broadcast Television Group.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters